

In support of HB 608

Chairman Lipps and Members of the House Committee:

Global Colon Cancer Association is writing in support of HB608. In cancer care, biomarkers are often used to help determine the best treatment for a patient. However, the reality is that not all communities are benefiting from the latest advancements in biomarker testing and precision medicine. Marginalized communities including communities of color, individuals with lower socioeconomic status, rural communities, and those receiving care in non-academic medical centers are less likely to receive biomarker testing.

We believe that improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities.

When diagnosed with cancer, every patient needs as many tools and opportunities to fight the disease. Biomarker testing can make all the difference and give patients that chance.

HB608 is an important step in achieving better outcomes and reducing costs by connecting patients to the most effective treatment for their cancer.

Sincerely,

Mialth

Nicole Sheahan President Global Colon Cancer Association

